Symbols / BBOT Stock $8.78 -2.12% BridgeBio Oncology Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
BBOT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Pedro J. Beltran M.D., Ph.D.
Exch · Country NGM · United States
Market Cap 702.69M
Enterprise Value 279.99M
Income -134.04M
Sales —
FCF (ttm) -74.19M
Book/sh 5.14
Cash/sh 5.32
Employees 92
Insider 10d —
IPO Feb 09, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.29
PEG —
P/S —
P/B 1.71
P/C —
EV/EBITDA -1.92
EV/Sales —
Quick Ratio 12.15
Current Ratio 12.34
Debt/Eq 0.67
LT Debt/Eq —
EPS (ttm) -4.30
EPS next Y -2.05
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-03-05
ROA -29.75%
ROE -48.23%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 80.03M
Shs Float 31.16M
Insider Own 27.22%
Instit Own 70.34%
Short Float —
Short Ratio 11.78
Short Interest 2.39M
52W High 14.87
vs 52W High -40.95%
52W Low 8.08
vs 52W Low 8.66%
Beta 0.51
Impl. Vol. —
Rel Volume 1.27
Avg Volume 302.06K
Volume 384.59K
Target (mean) $25.38
Tgt Median $23.50
Tgt Low $18.00
Tgt High $41.00
# Analysts 8
Recom Strong_buy
Prev Close $8.97
Price $8.78
Change -2.12%
About

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.38
Mean price target
2. Current target
$8.78
Latest analyst target
3. DCF / Fair value
$-16.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.78
Low
$18.00
High
$41.00
Mean
$25.38

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-06 main HC Wainwright & Co. Buy → Buy $29
2026-02-11 init Stifel — → Buy $23
2026-01-09 init Raymond James — → Outperform $24
2025-12-11 reit Wedbush Outperform → Outperform $25
2025-12-05 init Morgan Stanley — → Overweight $20
2025-11-25 reit Wedbush Outperform → Outperform $25
2025-11-13 main Oppenheimer Outperform → Outperform $22
2025-09-17 init Leerink Partners — → Outperform $25
2025-09-15 init HC Wainwright & Co. — → Buy $27
2025-09-04 init Oppenheimer — → Outperform $23
2025-08-18 init Wedbush — → Outperform $25
News
RSS: Latest BBOT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 MEHRA UNEEK Chief Financial Officer — 23,330 $0.00 $0
2026-03-10 BEN YONG Officer — 46,670 $0.00 $0
2026-03-10 BELTRAN PEDRO Officer — 46,670 $0.00 $0
2025-08-11 HOLMAN ALBERT A III Former — 30,000 — —
2025-08-11 SCHMID JOHN P Former — 30,000 — —
2025-08-11 MCKENNA MARK C Former — 30,000 — —
2025-08-11 CHEN BIHUA X. Director and Beneficial Owner of more than 10% of a Class of Security — 10,950,408 $0.00 $74,999,998
2025-08-11 CHEN BIHUA X. Director and Beneficial Owner of more than 10% of a Class of Security — 4,172,126 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
145.82
+80.33%
80.86
+24.84%
64.77
Research And Development
121.20
+65.78%
73.11
+29.88%
56.29
Selling General And Administration
24.62
+217.43%
7.76
-8.59%
8.48
General And Administrative Expense
24.62
+217.43%
7.76
-8.59%
8.48
Other Gand A
24.62
+217.43%
7.76
-8.59%
8.48
Total Expenses
145.82
+80.33%
80.86
+24.84%
64.77
Operating Income
-145.82
-80.33%
-80.86
-24.84%
-64.77
Total Operating Income As Reported
-145.82
-80.33%
-80.86
-24.84%
-64.77
EBITDA
-145.21
-80.04%
-80.66
-24.70%
-64.68
Normalized EBITDA
-145.21
-80.04%
-80.66
-24.70%
-64.68
Reconciled Depreciation
0.61
+193.27%
0.21
+126.09%
0.09
EBIT
-145.82
-80.33%
-80.86
-24.84%
-64.77
Net Income
-134.04
-80.47%
-74.28
-14.80%
-64.70
Pretax Income
-134.04
-80.47%
-74.28
-14.80%
-64.70
Net Non Operating Interest Income Expense
11.34
+77.87%
6.38
+8756.94%
0.07
Net Interest Income
11.34
+77.87%
6.38
+8756.94%
0.07
Interest Income Non Operating
11.34
+77.87%
6.38
+8756.94%
0.07
Interest Income
11.34
+77.87%
6.38
+8756.94%
0.07
Other Income Expense
0.43
+104.74%
0.21
—
Other Non Operating Income Expenses
0.43
+104.74%
0.21
—
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-134.04
-80.47%
-74.28
-14.80%
-64.70
Net Income From Continuing Operation Net Minority Interest
-134.04
-80.47%
-74.28
-14.80%
-64.70
Net Income From Continuing And Discontinued Operation
-134.04
-80.47%
-74.28
-14.80%
-64.70
Net Income Continuous Operations
-134.04
-80.47%
-74.28
-14.80%
-64.70
Normalized Income
-134.04
-80.47%
-74.28
-14.80%
-64.70
Net Income Common Stockholders
-134.04
-80.47%
-74.28
-14.80%
-64.70
Diluted EPS
—
-0.94
-14.80%
-0.82
Basic EPS
—
-0.94
-14.80%
-0.82
Basic Average Shares
—
79.20
+0.00%
79.20
Diluted Average Shares
—
79.20
+13.16%
69.99
Diluted NI Availto Com Stockholders
-134.04
-80.47%
-74.28
-14.80%
-64.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
448.38
+172.90%
164.30
+2665.08%
5.94
Current Assets
432.40
+172.47%
158.69
+3930.81%
3.94
Cash Cash Equivalents And Short Term Investments
425.46
+173.38%
155.63
+62152.40%
0.25
Cash And Cash Equivalents
373.69
+1111.26%
30.85
+12240.40%
0.25
Other Short Term Investments
51.77
-58.51%
124.78
0.00
Receivables
0.39
+376.54%
0.08
-95.30%
1.72
Other Current Assets
6.55
+119.72%
2.98
+51.78%
1.96
Total Non Current Assets
15.98
+185.04%
5.61
+179.70%
2.00
Net PPE
3.29
+570.61%
0.49
-17.79%
0.60
Gross PPE
3.29
+570.61%
0.49
—
Other Properties
3.29
+570.61%
0.49
—
Other Non Current Assets
12.70
+148.12%
5.12
+263.24%
1.41
Total Liabilities Net Minority Interest
37.28
-89.13%
342.94
+182.06%
121.58
Current Liabilities
35.04
+78.96%
19.58
+16.72%
16.77
Payables And Accrued Expenses
28.77
+127.38%
12.65
-24.57%
16.77
Payables
1.91
-46.36%
3.56
-73.13%
13.24
Accounts Payable
1.37
-55.30%
3.07
+434.61%
0.57
Current Accrued Expenses
26.86
+195.32%
9.10
+157.27%
3.54
Pensionand Other Post Retirement Benefit Plans Current
5.75
+50.38%
3.82
0.00
Current Debt And Capital Lease Obligation
0.52
—
—
Current Capital Lease Obligation
0.52
0.00
—
Other Current Liabilities
—
3.10
—
Total Non Current Liabilities Net Minority Interest
2.24
-99.31%
323.36
+208.52%
104.81
Long Term Debt And Capital Lease Obligation
2.24
0.00
—
Long Term Capital Lease Obligation
2.24
0.00
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
323.36
+208.52%
104.81
Stockholders Equity
411.10
+330.13%
-178.64
-54.48%
-115.64
Common Stock Equity
411.10
+330.13%
-178.64
-54.48%
-115.64
Capital Stock
0.01
0.00
0.00
Common Stock
0.01
0.00
0.00
Share Issued
79.99
+1.00%
79.20
+0.00%
79.20
Ordinary Shares Number
79.99
+1.00%
79.20
+0.00%
79.20
Additional Paid In Capital
767.64
+1663.15%
43.54
+33.52%
32.61
Retained Earnings
-356.57
-60.24%
-222.52
-50.10%
-148.25
Gains Losses Not Affecting Retained Earnings
0.02
-95.40%
0.35
0.00
Other Equity Adjustments
0.02
-95.40%
0.35
—
Total Equity Gross Minority Interest
411.10
+330.13%
-178.64
-54.48%
-115.64
Total Capitalization
411.10
+330.13%
-178.64
-54.48%
-115.64
Working Capital
397.36
+185.63%
139.11
+1183.60%
-12.84
Invested Capital
411.10
+330.13%
-178.64
-54.48%
-115.64
Total Debt
2.77
0.00
—
Capital Lease Obligations
2.77
0.00
—
Net Tangible Assets
411.10
+330.13%
-178.64
-54.48%
-115.64
Tangible Book Value
411.10
+330.13%
-178.64
-54.48%
-115.64
Duefrom Related Parties Current
0.39
+376.54%
0.08
-95.30%
1.72
Dueto Related Parties Current
0.53
+10.56%
0.48
-96.19%
12.66
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-113.89
-106.98%
-55.03
-5.66%
-52.08
Cash Flow From Continuing Operating Activities
-113.89
-106.98%
-55.03
-5.66%
-52.08
Net Income From Continuing Operations
-134.04
-80.47%
-74.28
-14.80%
-64.70
Depreciation Amortization Depletion
0.61
+193.27%
0.21
+126.09%
0.09
Depreciation
0.61
+193.27%
0.21
+126.09%
0.09
Depreciation And Amortization
0.61
+193.27%
0.21
+126.09%
0.09
Other Non Cash Items
0.72
+28.55%
0.56
—
Stock Based Compensation
5.87
+32.72%
4.42
-73.12%
16.46
Unrealized Gain Loss On Investment Securities
7.77
0.00
—
Change In Working Capital
6.43
-58.75%
15.59
+496.09%
-3.94
Change In Prepaid Assets
-3.42
-235.66%
-1.02
-938.78%
-0.10
Change In Payables And Accrued Expense
17.73
+64.89%
10.75
+8367.72%
0.13
Change In Accrued Expense
19.57
+137.06%
8.26
+5997.14%
-0.14
Change In Payable
-1.84
-173.66%
2.50
+835.58%
0.27
Change In Account Payable
-1.84
-173.66%
2.50
+835.58%
0.27
Change In Other Working Capital
-0.25
-102.69%
9.43
+469.09%
-2.56
Change In Other Current Assets
-7.58
-112.00%
-3.58
-153.62%
-1.41
Change In Other Current Liabilities
-0.05
0.00
—
Investing Cash Flow
73.33
+160.84%
-120.53
-4174.11%
-2.82
Cash Flow From Continuing Investing Activities
73.33
+160.84%
-120.53
-4174.11%
-2.82
Net PPE Purchase And Sale
-0.61
-1136.73%
-0.05
+88.16%
-0.41
Purchase Of PPE
-0.61
-1136.73%
-0.05
+88.16%
-0.41
Capital Expenditure
-0.61
-1136.73%
-0.05
+88.16%
-0.41
Net Investment Purchase And Sale
73.93
+160.16%
-122.89
0.00
Purchase Of Investment
-83.92
+45.66%
-154.43
0.00
Sale Of Investment
157.86
+400.44%
31.54
0.00
Net Other Investing Changes
—
2.41
+200.00%
-2.41
Financing Cash Flow
383.40
+85.86%
206.29
+274.23%
55.12
Cash Flow From Continuing Financing Activities
383.40
+85.86%
206.29
+274.23%
55.12
Net Common Stock Issuance
0.00
-100.00%
1.06
-70.70%
3.62
Proceeds From Stock Option Exercised
0.04
-13.46%
0.05
0.00
Net Other Financing Charges
361.13
—
—
Changes In Cash
342.84
+1015.53%
30.73
+13559.11%
0.23
Beginning Cash Position
30.98
+12293.20%
0.25
+900.00%
0.03
End Cash Position
373.82
+1106.53%
30.98
+12293.20%
0.25
Free Cash Flow
-114.50
-107.89%
-55.08
-4.92%
-52.49
Amortization Of Securities
-1.26
+18.34%
-1.54
0.00
Common Stock Issuance
0.00
-100.00%
1.06
-70.70%
3.62
Issuance Of Capital Stock
22.22
-89.23%
206.24
+274.13%
55.12
Net Preferred Stock Issuance
22.22
-89.17%
205.18
+298.40%
51.50
Preferred Stock Issuance
22.22
-89.17%
205.18
+298.40%
51.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category